



**Figure 5A**



**Figure 5B**



**Figure 5C**






Figure 5D





Days after the initial dose of 5-FU

Phylogix

Figure 6

# Improved Survival of FRIL-Treated Mice




Figure 7




Figure 8

# FRIL Prevents Wasting of Mice in the Two-Dose 5-FU Chemoprotection Model




Figure 9A




Figure 9B

Day 0 (day 0 - 1.57 x10<sup>3</sup> cells)




Figure 10

Kollet and Lapidot  
Weizmann Institute

Phylogix

# Cytokines Expand Cell Number and Progenitors After Culture in FRIL

Viable cells




Figure 11A

Progenitors








Figure 11B

Kollet et al, Weizmann Institute


Phylogix



Phylogix


# Activation Status of FRIL-Selected Cord Blood Cells

Figure 2A



**CD38**


Figure 2B




**CD38**

10083936 1022702

# Response of FRIL-Selected CB Cells to Endothelial and Hematopoietic Stimuli




**Figure 3A**



**Figure 3B**

# Phylogix

# Receptor Tyrosine Kinase (RTK) Expression in FRIL-Selected CB Cell Populations



Key:

- MNC
- FRIL<sup>+</sup>
- 3 CD34<sup>+</sup>

Other RTK<sup>±</sup>:

- Kit
- Flk1/KDR
- FLT4

Phylogix

Figure 4